← All trials
NCT04270591
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2019
- Primary completion
- Feb 28, 2021
- Completion date
- Jun 13, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 68
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ShangHai HaiHe PharmaceuticalLead sponsor
- Zhengzhou UniversityOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Changhai HospitalOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Harbin Medical UniversityOverall official - principal investigator
- Nanjing Medical UniversityOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Shanghai Chest Hospital, Shanghai, ChinaOverall official - principal investigator
- The Chest Hospital of Anhui ProvinceOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Anhui Medical UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.